Clinical Trials Browser

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Anus Neoplasms, Appendiceal Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lip Neoplasms, Lung Neoplasms, Mesothelioma, Mouth Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Ductal, Small Cell Lung Carcinoma

Clinical Trials

Treat Primary and Metastatic Liver Tumors

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

FDGal PET/CT to Detect Hepatocellular Carcinoma

A Study to Evaluate Vaccines Against COVID-19 in the Real World

ECHAPS

Microwave Ablation of Resectable Liver Tumors

Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry

Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma

Gut Microbiota in People With Hepatocellular Carcinoma (HCC)

GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start

SLAMF3

ROLFH

Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events

PriMPa

Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer